The most groundbreaking individual studies from the latest supplement and nutrition research — in plain language, with the evidence caveats built in. Research signals worth knowing about, not health advice.
This is early animal research on a specific strain, so while the anti-inflammatory signal is promising, it's far from being a proven supplement for people with colitis.
This single, early trial suggests folic acid may help offset cognitive decline in people with small vessel disease, but because it is among the first such studies, the result needs confirmation and may not extend to healthier populations.
This is one of the first pooled analyses to suggest vitamin D3, not D2, can improve how cells respond to insulin in people with obesity and metabolic syndrome, but a single meta-analysis — especially one that saw no benefit for a closely related outcome — is far from conclusive.
This is the first indexed meta‑analysis on spirulina for insulin sensitivity, so while the drop in HOMA‑IR is promising, we can't yet say how much to take or who benefits most.
This is the first large-scale synthesis to link low vitamin D levels to a higher risk of surgical infections, but because it pools observational data rather than randomized trials, it can't prove that raising vitamin D levels would lower that risk — a key gap that limits how much we can act on it.
This meta-analysis adds to a moderate body of evidence (5 of 7 studies showing benefit) that ginkgo may help cognition in a very specific clinical population — people with dementia after a cerebral infarction — but the small effect size and narrow patient group mean the results don't apply to healthy adults or general memory concerns.
This large effect is promising for a specific clinical scenario, but because the studies are among the first on this pairing and the certainty is low, the finding needs replication before it can be considered reliable for broader use.
This is an unusually strong signal from a small body of evidence, but it's too early to assume healthy people would see any similar benefit.
This null result from a double-blind randomized trial challenges the assumption that boosting prenatal vitamin D will meaningfully shape children's bone architecture, though it's among the first studies to look at this specific question, so the picture is far from settled.
This null result challenges any assumption that vitamin D alone meaningfully alters sclerostin, a protein that regulates bone formation, at this dose in healthy seniors — though the picture is far from settled, as this is one of the first studies to test the specific pairing head-to-head.
The finding is based on three randomized trials, all pointing in the same direction, making the evidence moderately reliable — but it only applies to patients with metabolic-associated fatty liver disease, not to healthy individuals.
This is an early, promising signal from a small set of trials, but the evidence is too shaky to act on — larger, more rigorous studies are needed before anyone should change their treatment plan.
This is the strongest signal yet that swapping in avocado for less healthy fats and sugars can meaningfully lower triglycerides, but the overall evidence is still weak and inconsistent, so don't treat this as settled.
This is an early look at a specific pairing, not a standalone verdict on berberine; the results are promising but come from a single clinical trial in people with type 2 diabetes, so they don't yet apply to the general curious supplement-taker.
This rigorous, double-blind study challenges the common belief that green tea prevents colorectal polyps, though a possible benefit in a genetic subgroup needs replication before any conclusion can be drawn — the overall evidence remains too thin to change practice.
This is one of the first indexed meta-analyses to bundle berberine with probiotics and synbiotics, so the evidence is still early; the effect is real but small enough that it likely matters most as a complement to standard diabetes care, not a replacement.
This is early data from a clinical population, so the finding is intriguing but far from ready to apply to healthy adults or to guide supplement decisions.
This review solidifies folate's power against two specific birth-related conditions, but any link to obesity is still a gap in the evidence, not a finding.
This contradicts the popular notion that ironweed is an effective smoking-cessation aid overall — the positive signal is only temporary, and the evidence comes from a single country (Thailand) with no long-term edge over established treatments like nicotine patches.
This contradicts the popular belief that high-dose vitamin C is a life-saver in acute COVID-19, but because it's one of the first indexed meta-analyses on the topic and the data came from unblinded clinical settings, the picture is far from settled.
This early, small study suggests a mix of black cohosh, soy isoflavones, and SDG lignans may offer substantial relief from physical menopausal symptoms, but because it tested a blend, we don't know how much credit black cohosh deserves — and the finding needs replication before trusting it broadly.
This is the first solid, pooled evidence that okra may help with blood sugar control in a clinical population, but the effect size comes from moderate-quality evidence and only three studies have looked at this specific pairing — so it's interesting, not definitive.
This is a very large effect, but it comes from a handful of small prevention trials where the quality of the evidence is low, so the real-world benefit is far from settled.
This suggests that a simple kitchen staple might offer a non-drug alternative for a specific, harsh side effect of radiotherapy — but the result comes from a single study in a clinical population, so it doesn't yet apply to everyday skin care or other types of dermatitis.
While the effect size is unusually large for a supplement in a meta-analysis, this finding comes from a single, unblinded systematic review of 552 athletes in hot conditions, so it’s a promising lead, not a settled fact.
This is the first meta-analysis to pool data on honey for post-tonsillectomy pain in kids, and while the average effect looks promising, the underlying studies disagreed so much (I² = 92.5%) that the result is far from solid — treat it as a signal worth testing, not a recommendation.
This is the first indexed systematic review on astaxanthin for inflammation, so the signal is real but narrow — it's seen in people with existing health conditions, and the picture for healthy adults is still an open question.
This single randomized trial suggests vitamin C could be a useful option for managing postoperative pain without the metabolic side effects of steroids, but the result is from a small clinical population undergoing major surgery, so it doesn't tell us whether vitamin C works for everyday pain in healthy people.
This is a single, rigorous trial in a specific clinical population, so while the effect is large and statistically significant, it's premature to assume the same degree of benefit in younger people, men, or healthy adults.
This well-designed, five-year Finnish trial found no statistically significant protection against dementia from vitamin D in people who were already replete — but with only 45 total dementia cases across all arms, the study lacked the power to detect a small effect, so the question isn't settled.